Xiaoling L. Li

Shenyang, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Journal: JAMA
Published: June 17, 2026

Association of body mass index and serum markers with immune-related adverse events in lung cancer patients receiving immune checkpoint inhibitors.

Association of body mass index and serum markers with immune-related adverse events in lung cancer patients receiving immune checkpoint inhibitors.

Journal: Journal of thoracic disease
Published: March 24, 2026

Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis.

Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis.

Journal: JTO clinical and research reports
Published: November 07, 2025

Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer.

Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer.

Journal: Translational lung cancer research
Published: June 03, 2025

Clinical outcomes and therapeutic modalities in older Chinese patients with MCL: a multi-center real-world retrospective study.

Clinical outcomes and therapeutic modalities in older Chinese patients with MCL: a multi-center real-world retrospective study.

Journal: Annals of medicine
Published: March 28, 2025

NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report.

NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report.

Journal: Frontiers in pharmacology
Published: February 06, 2025

A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).

A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).

Journal: Future oncology (London, England)
Published: December 04, 2024

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.

Journal: Signal transduction and targeted therapy
Published: August 25, 2024

Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report.

Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report.

Journal: Medicine
Published: July 12, 2024

Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.

Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.

Journal: JAMA
Published: May 31, 2024

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 22, 2024

Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.

Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.

Journal: Cancer cell
Published: January 03, 2024
Showing 1-12 of 39

Last Updated: 09/26/2026